NO20015021L - Fremgangsmåte til å nedregulere IL-5 aktivitet - Google Patents
Fremgangsmåte til å nedregulere IL-5 aktivitetInfo
- Publication number
- NO20015021L NO20015021L NO20015021A NO20015021A NO20015021L NO 20015021 L NO20015021 L NO 20015021L NO 20015021 A NO20015021 A NO 20015021A NO 20015021 A NO20015021 A NO 20015021A NO 20015021 L NO20015021 L NO 20015021L
- Authority
- NO
- Norway
- Prior art keywords
- modified
- present
- ils
- well
- analogs
- Prior art date
Links
- 102000000743 Interleukin-5 Human genes 0.000 title abstract 9
- 108010002616 Interleukin-5 Proteins 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 6
- 230000002222 downregulating effect Effects 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 229940100602 interleukin-5 Drugs 0.000 abstract 8
- 210000004027 cell Anatomy 0.000 abstract 3
- 150000007523 nucleic acids Chemical group 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 210000000222 eosinocyte Anatomy 0.000 abstract 1
- 230000002327 eosinophilic effect Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse angår forbedringer med hensyn til terapi og hindring av tilstander som eret forhøyet nivå av eosinofile leukocytter, det vil si tilstander så som astma eller andre kroniske allergiske sykdommer. Det er tilveiebrakt en fremgangsmåte for nedregulering av interleukin 5 (IL5) ved å muliggjøre produksjonen av antistoffer mot IL5 for derved å redusere aktivitetsnivået for de eosinofile cellene. Oppfinnelsen tilveiebringer også fremgangsmåter for fremstilling av modifisert ILS som kan brukes i denne fremgangsmåten så vel som for det modifiserte IL5 som sådan. Foreliggende oppfinnelse innbefatter også nukleinsyrefragmenter som koder modifisert IL5 så vel som vektorer som inkorporerer disse nukleinsyrerfagmentene, foruten vertsceller og cellelinjer som er transformert med disse. Oppfinnelsen tilveiebringer også en fremgangsmåte for identifikasjon av ILS-analoger som kan brukes i foreliggende fremgangsmåte så vel som for blandinger som innbefatter modifisert IL5, eller som innbefatter nukleinsyrer som koder IL5-analogene. Den foretrukne utførelse av foreliggende oppfinnelse innbefatter bruken av varianter av IL5 hvor det er innfart fremmede T-hjelpeepitoper for derved å indusere produksjonen av tverr-reaktive antistoffer som er i stand til å binde seg til autolog ILS.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199900552 | 1999-04-23 | ||
| US13281199P | 1999-05-06 | 1999-05-06 | |
| PCT/DK2000/000205 WO2000065058A1 (en) | 1999-04-23 | 2000-04-19 | Method for down-regulating il5 activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20015021D0 NO20015021D0 (no) | 2001-10-15 |
| NO20015021L true NO20015021L (no) | 2001-12-21 |
Family
ID=26064209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20015021A NO20015021L (no) | 1999-04-23 | 2001-10-15 | Fremgangsmåte til å nedregulere IL-5 aktivitet |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7285273B1 (no) |
| EP (1) | EP1173573A1 (no) |
| JP (1) | JP2002543098A (no) |
| KR (1) | KR20020084841A (no) |
| CN (1) | CN1355846A (no) |
| AU (1) | AU777952B2 (no) |
| CA (1) | CA2370391A1 (no) |
| CZ (1) | CZ20013709A3 (no) |
| EA (1) | EA200101125A1 (no) |
| EE (1) | EE200100552A (no) |
| HR (1) | HRP20010824A2 (no) |
| HU (1) | HUP0200958A3 (no) |
| IL (1) | IL145786A0 (no) |
| MX (1) | MXPA01010625A (no) |
| NO (1) | NO20015021L (no) |
| PL (1) | PL351986A1 (no) |
| SK (1) | SK14832001A3 (no) |
| TR (1) | TR200103046T2 (no) |
| WO (1) | WO2000065058A1 (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9706957D0 (en) | 1997-04-05 | 1997-05-21 | Smithkline Beecham Plc | Formulation |
| GB9820525D0 (en) | 1998-09-21 | 1998-11-11 | Allergy Therapeutics Ltd | Formulation |
| US6913749B2 (en) | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| GB0000891D0 (en) * | 2000-01-14 | 2000-03-08 | Allergy Therapeutics Ltd | Formulation |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
| AU2002363382B2 (en) * | 2001-11-07 | 2007-07-19 | Cytos Biotechnology Ag | Antigen arrays presenting IL-5, IL-3 or eotaxin for treatment of allergic eosinophilic diseases |
| JP4533626B2 (ja) * | 2001-11-07 | 2010-09-01 | サイトス バイオテクノロジー アーゲー | アレルギー性好酸球性疾患を治療するための抗原アレイ |
| CN1615316A (zh) * | 2001-11-16 | 2005-05-11 | 法麦克萨有限公司 | 多聚体蛋白质的新免疫原性模拟物 |
| AU2003259374A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Vaccine comprising il-13 and an adjuvant |
| WO2004019974A2 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use |
| EP1608316A4 (en) * | 2003-03-24 | 2007-08-15 | Mercia Pharma Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY CONDITIONS |
| CN103091499B (zh) * | 2013-01-23 | 2015-07-08 | 三峡大学 | 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用 |
| ES2949029T3 (es) * | 2013-02-22 | 2023-09-25 | Regeneron Pharma | Células murinas que expresan complejo mayor de histocompatibilidad humanizado |
| AU2014249150B2 (en) * | 2013-03-11 | 2020-04-02 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules |
| CN113307869B (zh) * | 2020-10-30 | 2023-01-06 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096704A (en) | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
| FR2677654B1 (fr) | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
| WO1993023076A1 (en) | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
| US5616488A (en) | 1992-12-07 | 1997-04-01 | Ribozyme Pharmaceuticals, Inc. | IL-5 targeted ribozymes |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| PT735893E (pt) | 1993-09-14 | 2009-03-06 | Pharmexa Inc | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária |
| WO1995026365A1 (en) * | 1994-03-28 | 1995-10-05 | United Biomedical, Inc. | Synthetic peptide based immunogens for the treatment of allergy |
| AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
| JP3872813B2 (ja) | 1994-05-18 | 2007-01-24 | エス．ピー．アイ． シンセティック ペプチデス インコーポレイテッド | ヘテロダイマーポリペプチド免疫原キャリア組成物および方法 |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| WO1997000321A1 (en) | 1995-06-14 | 1997-01-03 | Commonwealth Scientific And Industrial Research Organisation | Immune response modulators and uses therefor |
| CA2745736C (en) | 1996-10-23 | 2016-11-22 | The Trustees Of The University Of Pennsylvania | Immunotherapy and improved vaccines |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| EP1005374B1 (en) | 1997-01-22 | 2007-04-18 | Zycos Inc. | Microparticles for delivery of nucleic acid |
| AU7132098A (en) | 1997-04-18 | 1998-11-13 | Tanox Biosystems, Inc. | Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases |
| WO2000020027A2 (en) * | 1998-10-05 | 2000-04-13 | M & E Biotech A/S | Methods for therapeutic vaccination |
-
2000
- 2000-04-19 WO PCT/DK2000/000205 patent/WO2000065058A1/en not_active Application Discontinuation
- 2000-04-19 PL PL00351986A patent/PL351986A1/xx not_active Application Discontinuation
- 2000-04-19 HU HU0200958A patent/HUP0200958A3/hu unknown
- 2000-04-19 IL IL14578600A patent/IL145786A0/xx unknown
- 2000-04-19 KR KR1020017013585A patent/KR20020084841A/ko not_active Application Discontinuation
- 2000-04-19 CN CN00806367A patent/CN1355846A/zh active Pending
- 2000-04-19 TR TR2001/03046T patent/TR200103046T2/xx unknown
- 2000-04-19 EP EP00920423A patent/EP1173573A1/en not_active Ceased
- 2000-04-19 AU AU41008/00A patent/AU777952B2/en not_active Ceased
- 2000-04-19 US US09/980,916 patent/US7285273B1/en not_active Expired - Fee Related
- 2000-04-19 MX MXPA01010625A patent/MXPA01010625A/es unknown
- 2000-04-19 EE EEP200100552A patent/EE200100552A/xx unknown
- 2000-04-19 CZ CZ20013709A patent/CZ20013709A3/cs unknown
- 2000-04-19 CA CA002370391A patent/CA2370391A1/en not_active Abandoned
- 2000-04-19 EA EA200101125A patent/EA200101125A1/ru unknown
- 2000-04-19 JP JP2000614393A patent/JP2002543098A/ja active Pending
- 2000-04-19 SK SK1483-2001A patent/SK14832001A3/sk unknown
- 2000-04-21 US US09/556,818 patent/US6746669B1/en not_active Expired - Fee Related
-
2001
- 2001-10-15 NO NO20015021A patent/NO20015021L/no not_active Application Discontinuation
- 2001-11-08 HR HR20010824A patent/HRP20010824A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SK14832001A3 (sk) | 2003-02-04 |
| TR200103046T2 (tr) | 2002-06-21 |
| US7285273B1 (en) | 2007-10-23 |
| KR20020084841A (ko) | 2002-11-11 |
| EE200100552A (et) | 2002-12-16 |
| CN1355846A (zh) | 2002-06-26 |
| JP2002543098A (ja) | 2002-12-17 |
| WO2000065058A1 (en) | 2000-11-02 |
| HRP20010824A2 (en) | 2002-12-31 |
| AU777952B2 (en) | 2004-11-04 |
| MXPA01010625A (es) | 2003-09-04 |
| EP1173573A1 (en) | 2002-01-23 |
| HUP0200958A3 (en) | 2004-11-29 |
| NO20015021D0 (no) | 2001-10-15 |
| US6746669B1 (en) | 2004-06-08 |
| HUP0200958A2 (en) | 2002-06-29 |
| CZ20013709A3 (cs) | 2002-11-13 |
| EA200101125A1 (ru) | 2002-04-25 |
| IL145786A0 (en) | 2002-07-25 |
| PL351986A1 (en) | 2003-07-14 |
| AU4100800A (en) | 2000-11-10 |
| CA2370391A1 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20015021L (no) | Fremgangsmåte til å nedregulere IL-5 aktivitet | |
| Koppelman et al. | Purification and immunoglobulin E‐binding properties of peanut allergen Ara h 6: evidence for cross‐reactivity with Ara h 2 | |
| Kettner et al. | Api m 6: a new bee venom allergen | |
| DE69924392D1 (de) | Verfahren zur hemmung der aktivität von osteoprotegerin-liganden | |
| JPS62169728A (ja) | トロンビン結合性物質およびその製法 | |
| Gavrovic-Jankulovic et al. | A novel recombinantly produced banana lectin isoform is a valuable tool for glycoproteomics and a potent modulator of the proliferation response in CD3+, CD4+, and CD8+ populations of human PBMCs | |
| WO1998014596A3 (en) | Disease associated protein tyrosine phosphatases | |
| Grobe et al. | Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases | |
| Hoffman | Allergens in Hymenoptera venom XVI: Studies of the structures and cross-reactivities of vespid venom phospholipases | |
| EP1219301B1 (en) | Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins | |
| Welle et al. | Properties and solubilization of the prenyltransferase of isoflavonoid phytoalexin biosynthesis in soybean | |
| WO1998018822A3 (en) | Novel human lim proteins | |
| Wopfner et al. | The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level | |
| WO1998025956A3 (en) | Human GTP-binding proteins | |
| Kohama et al. | Ca2+-binding light chain of Physarum myosin confers inhibitory Ca2+-sensitivity on Actin-myosin-ATP interaction via actin | |
| Nakayama et al. | Affinity purification of nicotinic acetylcholine receptor from rat brain | |
| AU776154B2 (en) | Method for isolating and purifying grass pollen allergens | |
| EP3430390A1 (en) | Molecular origin of allergy | |
| Hülsmann et al. | Cardiac lipoprotein lipase: effects of lipopolysaccharide and tumor necrosis factor | |
| Etzler | Isolation and characterization of subunits of DB58, a lectin from the stems and leaves of Dolichos biflorus | |
| Dhyani et al. | A clinically relevant major cross‐reactive allergen from mesquite tree pollen | |
| WO2012105541A1 (ja) | 新規ヒノキ花粉アレルゲン | |
| Müller et al. | Ubiquitin and ubiquitination in cells from the marine sponge Geodia cydonium | |
| WO1998018942A3 (en) | Novel human rab proteins | |
| WO1998036068A3 (en) | Human p24 vesicle proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |